Glyko Biomedical Ltd.'s 21%-owned Affiliate, BioMarin, Announces Upcoming Clinical Trial Data Presentations Regarding Aldurazyme for MPS I and Aryplase for MPS VI.Business Editors/Health & Medical Writers 7th Intl. Symposium on Mucopolysaccharide mucopolysaccharide (my  'kəpŏlēsăk`ərīd), class of polysaccharide molecules, also known as glycosaminoglycans, composed of amino-sugars chemically linked into and Related Diseases 3rd Scientific Lysosomal lysosomal pertaining to or emanating from lysosomes. lysosomal enzymes enzymes located in the lysosomes. lysosomal phospholipidosis Storage Disorders Congress NOVATO, Calif.--(BW HealthWire)--June 14, 2002 Glyko Biomedical Ltd.'s (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :GLYK)(TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :GBL)(BVD-Berlin:GLY Gly glycine. Gly abbr. glycine Gly glycine. ) 21%-owned affiliate, BioMarin Pharmaceutical Inc. (Nasdaq:BMRN)(Swiss SWX New Market: BMRN), today announced that investigators will present new data from the double-blind and open-label extension portions of the Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. of Aldurazyme(TM) as well as extension data from the Phase 1 clinical trial phase 1 clinical trial Phase 1 study. See Phase study. of Aryplase(TM) at the 7th International Symposium on Mucopolysaccharide and Related Diseases and the 3rd Scientific Lysosomal Storage Disorders Congress in Paris, France later this month. Aldurazyme (laronidase) is an investigational enzyme replacement therapy Enzyme replacement therapy is a medical treatment replacing an enzyme in patients in whom that particular enzyme is deficient or absent. Usually this is done by giving the patient an intravenous (IV) infusion containing the enzyme. for mucopolysaccharidosis I (MPS I) that is being developed by BioMarin through a joint venture with Genzyme (Nasdaq:GENZ). Aryplase (recombinant human arylsulfatase B) is an investigational enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI). Both MPS I and MPS VI are life-threatening lysosomal storage disorders for which no specific drug treatments currently exist. On Friday, June 21, Joseph Muenzer, M.D., Ph.D., Associate Professor of Pediatrics at the University of North Carolina at Chapel Hill The University of North Carolina at Chapel Hill is a public, coeducational, research university located in Chapel Hill, North Carolina, United States. Also known as The University of North Carolina, Carolina, North Carolina, or simply UNC , will present findings on the clinical manifestations of MPS I derived from baseline evaluations of the 45 patients enrolled in the Phase 3 Aldurazyme trial. On Saturday, June 22, Ed Wraith, M.D., of the Willink Biochemical Genetics Unit at the Royal Manchester Children's Hospital Royal Manchester Children's Hospital was founded in 1829 as a small dispensary based in Salford, Greater Manchester, England for the treatment of sick children. It was the first such hospital in Great Britain and by 1855 had developed to a six-bed hospital. , Manchester, UK, will present detailed results from the six-month placebo-controlled portion of the Phase 3 Aldurazyme trial as well as preliminary results from the six-month open-label Phase 3 extension study. Also on June 22, Paul Harmatz, M.D., Associate Director, Pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children. pe·di·at·ric adj. Of or relating to pediatrics. Clinical Research Center, Children's Hospital and Research Center at Oakland, California, will present 48 weeks of data from Phase 1 Aryplase trial, which includes 24 weeks of data from the ongoing extension study. The 7th International Symposium on Mucopolysaccharide and Related Diseases and the 3rd Scientific Lysosomal Storage Disorders Congress will be held in Paris, France at the Hotel Sofitel from June 20 to June 23. Additional information on this event can be found at the following website: http://www.mpssociety.co.uk/conference.htm. Glyko Biomedical Ltd.'s principal asset is a 21% ownership in the capital stock of BioMarin Pharmaceutical Inc. BioMarin specializes in the development and commercialization of therapeutic enzyme products to treat serious, life-threatening diseases and conditions. This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including the following potential future products: Aldurazyme for the treatment of MPS I and Aryplase for the treatment of MPS VI. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. Results may differ materially depending on the progress of BioMarin's product programs, the actual results of the current and planned clinical trials and the results of the trials that will be presented at the above described conference, actions of regulatory authorities, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission such as 10Q, 10K and 8K reports. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise. Aldurazyme is a trademark of BioMarin/Genzyme LLC. All rights reserved. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion